## Abstract Levels of familial expressed emotion during an acute episode are consistently associated with rates of recurrence among bipolar patients. This article briefly reviews the evidence for expressed emotion (EE) as a prognostic indicator and then illustrates family‐focused treatment (FFT) wi
Allostatic load in bipolar disorder: Implications for pathophysiology and treatment
✍ Scribed by Flavio Kapczinski; Eduard Vieta; Ana Cristina Andreazza; Benicio N. Frey; Fabiano A. Gomes; Juliana Tramontina; Marcia Kauer-Sant’Anna; Rodrigo Grassi-Oliveira; Robert M. Post
- Publisher
- Elsevier Science
- Year
- 2008
- Tongue
- English
- Weight
- 605 KB
- Volume
- 32
- Category
- Article
- ISSN
- 0149-7634
No coin nor oath required. For personal study only.
✦ Synopsis
Current literature on the effects of chronic stress in general health converges to the concept of allostatic load (AL). AL is the bodily 'wear and tear' that emerges with sustained allostatic states. In the field of bipolar disorder (BD), AL offers an important clue as to why patients who undergo recurrent mood episodes are clinically perceived as less resilient. In addition, AL helps explaining the cumulative disruptive health effects of intermittent episodes and stressors. Stress- and episode-induced changes in brain regions involved in the emotional circuitry may lead to dysfunctional processing of information, which would render BD patients more vulnerable to subsequent environmental stressors, episodes, and drugs of abuse. Mood stabilizing agents exert opposite effects than chronic stress in neurons, increasing neuroprotective factors what may help to quench the cycle of affective episode recurrence and neural and bodily deterioration. Therefore, AL provides an explanatory link to apparently unrelated findings such as cognitive impairment and higher rates of physical comorbidity and mortality that are observed in the course of BD and further highlight the importance of effective long-term prophylaxis.
📜 SIMILAR VOLUMES
## Abstract Bipolar disorders are heterogeneous disorders often requiring multimodality treatment. The expanding pharmacopeia for bipolar disorders invites the need for a treatment framework that both recognizes and anticipates the multidimensionality and comorbidity of the illness. No available ne